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In previous research, Hugan Qingzhi, a traditional Chinese medicine, was shown to have
protective effects against hepatic steatosis. However, its activity against non-alcoholic
fatty liver disease (NAFLD) and the mechanisms by which it exerts its effects remain
unknown. In the present study, the effects of Hugan Qingzhi on free fatty acid (FFA)-
induced L02 cells were examined. The techniques of iTRAQ labeling, together with
strong cation exchange-non-liquid chromatography–tandem mass spectrometry (SCX-
non-LC-MS/MS) analysis and serum pharmacology, were used to evaluate the effects
of Hugan Qingzhi-medicated serum on FFA-induced L02 hepatocyte injury. Results
identified 355 differentially expressed proteins following FFA treatment, compared
with a control group; 359 altered proteins in the Hugan Qingzhi high dose + FFA
treatment group, compared with the FFA treatment group; and 365 altered proteins
in the Hugan Qingzhi high dose + FFA treatment group, compared with the control
group. Based on the Kyoto Encyclopedia of Gene and Genomes pathway enrichment
analysis, it is concluded that several pathways including those of microbial metabolism in
diverse environments, fatty acid metabolism, peroxisome proliferator activated receptor
signaling, and mitogen-activated protein kinase signaling are closely associated with
the effects of Hugan Qingzhi-medicated serum in FFA-induced L02 hepatocyte injury.
Furthermore, several differentially expressed proteins, including heat shock protein 27
(HSP27), acetyl-CoA acetyltransferase 1, calnexin, and integrin-linked kinase, were
validated by western blotting. A target-specific HSP27 siRNA was used to investigate
further the function of HSP27, and it was found that HSP27 might have a key
role in the observable effects of Hugan Qingzhi-medicated serum in FFA-induced
L02 hepatocyte injury. The results not only confirmed that Hugan Qingzhi exhibits a
significant protective effect in FFA-induced L02 hepatocyte injury, but also suggest
insights into the mechanism of such protective effects.
Keywords: Hugan Qingzhi (HQT), non-alcoholic fatty liver disease, isobaric tags for relative and absolute
quantitation (iTRAQ), proteomics, hepatocyte, non-alcoholic fatty liver disease (NAFLD)
Abbreviations: DEPs, differentially expressed proteins; FFA, free fatty acid; GO, Gene Ontology; HQT, Hugan Qingzhi;
iTRAQ, isobaric tags for relative and absolute quantification; KEGG, Kyoto Encyclopedia of Gene and Genomes.
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INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is defined as
the presence of hepatic steatosis in the absence of any
secondary causes of hepatic accumulation, such as significant
alcohol consumption, steatogenic drugs, or hereditary disorders.
Clinically, metabolic syndrome and its many components such
as obesity, diabetes mellitus, and dyslipidemia (Angulo, 2002) are
closely associated with NAFLD. As a clinicopathologic syndrome,
NAFLD includes a spectrum of liver disorders, ranging from
steatosis to steatohepatitis and fibrosis (Sheth et al., 1997;
Brunt et al., 1999). Non-alcoholic steatohepatitis (NASH) is
a more aggressive condition within the spectrum of NAFLD,
characterized by steatosis, inflammation, and hepatocyte injury
(ballooning degeneration) with or without cirrhosis (Sheth et al.,
1997; Brunt et al., 1999; Angulo, 2002). Although many risk
factors are known to play a pivotal role in the development
of NAFLD, its pathogenesis and progression remain poorly
understood (Farrell, 2002; Guturu and Duchini, 2012). Thus,
it is necessary to elucidate the overall processes and signaling
pathways of NAFLD and the mechanisms associated with its
treatment.
Within recent years, proteomics has been widely used in
the life sciences to detect differentially expressed proteins and
novel targets, and discover the associated mechanisms of action
(Lai et al., 2015; Pu et al., 2015; Wei et al., 2016). Isobaric
Tags for Relative and Absolute Quantification (iTRAQ) is a
novel technique developed by Applied Biosystems Incorporation
(ABI) with many advantages, such as high throughput, high
sensitivity, and superior accuracy, and has grown to be a robust
method in comparative proteomics (Treumann and Thiede,
2010).
Hugan Qingzhi (HQT) is a traditional Chinese medicine
used for treatment of NAFLD. Its therapeutic effects on NAFLD
have been confirmed in previous studies (Yin et al., 2014; Tang
et al., 2015). It consists mainly of five plant materials: including
Rhizoma Alismatis, Fructus Crataegi, Pollen Typhae, Folium
Nelumbinis, and Radix Notoginseng (Yin et al., 2014). However,
its complex composition poses considerable challenges for studies
on the mechanisms of HQT, because the effect of direct addition
of a crude drug to an in vitro system does not reflect the actual
efficacy of the drug (Yin et al., 2014). To minimize interference
between the physical and chemical characteristics of crude drugs
in an in vitro study, the experimental conditions should be as
similar as possible to those of the in vivo environment (Bochu
et al., 2005; Meng et al., 2012; Yin et al., 2014). Thus, serum
pharmacology coupled with iTRAQ were used in the present
study to determine the protective effect of HQT in a free fatty
acid (FFA)-induced L02 hepatocyte injury model.
MATERIALS AND METHODS
Plant Material Extract and Preparation of
HQT
Preparation of HQT has been described in previous studies
(Yin et al., 2014). The method entailed boiling a mixture of
30% Rhizoma Alismatis, 30% Fructus Crataegi, 15% Pollen
Typhae, and 20% Folium Nelumbinis, followed by refluxing
in 70% ethanol (6:1, v/w) for 2 h. The ethanol extract was
then collected. The residue was filtered and again extracted
by the aforementioned method. The ethanol extracts were
pooled and evaporated to dryness under reduced pressure. The
yield of the original dried mixture was 14.45% (w/w). Radix
Notoginseng (5%) was then ground, sifted, and added to the
dried extract to produce HQT. The basic quality of HQT was
checked by thin-layer chromatography and high-performance
liquid chromatography (HPLC) analyses (Zhou et al., 2012).
Preparation of HQT-Medicated Serum
A vehicle control group, three groups of different doses of HQT-
medicated serum (low, moderate, and high), and fenofibrate-
medicated serum (FF) were produced according to methods
described in a previous study (Yin et al., 2014). Thirty male
Sprague Dawley rats (weighing 200 ± 20 g), purchased from
the Animal Experiment Center of Southern Medical University,
Guangzhou, China, were maintained on a regular 12-h light/dark
cycle at 25–28◦C for a week. The rats were randomly divided
into five groups and orally administered different doses of HQT,
fenofibrate, or 1 mL/100 g of saline for 7 days (Table 1) (Yin et al.,
2014). One hour after the final treatment, blood was collected
aseptically via the abdominal aorta and centrifuged. The serum
from the same group was then pooled, filtered via 0.22 µm filters,
inactivated at 56◦C for 30 min, and stored at −80◦C. Results
of HPLC analysis of HQT-medicated serum were reported in a
previous study (Yin et al., 2014). All animal experiments were
approved by the Southern Medical University Animal Ethics
Committee and carried out in accordance with the institutional
guidelines.
Cell Culture and Experiment Design
Human hepatocyte cell line L02 was obtained from China Cell
Culture Center (Shanghai, China) and cultured in RPMI-1640
Medium (Gibco, USA), containing 10% fetal bovine serum
(Gibco, USA) at 37◦C, under 5% CO2. The cells were divided
into six groups as follows: the control group; FFA (oleic acid :
palmitic acid at 2:1) group; FFA+ 10% low dose HQT-medicated
serum group (HL); FFA + 10% moderate dose HQT-medicated
serum group (HM); FFA + 10% high dose HQT-medicated
serum group (HH); and FFA+ 10% fenofibrate-medicated serum
(FF). To verify whether the differences observed with the HQT-
medicated serum were attributable to HQT rather than the
serum, 10% vehicle serum control was added to the control and
TABLE 1 | Data on medicated serum preparation for each experimental
group.
Group information of medicated serum Dosage
Vehicle control group 1 mL/100 g of saline/day
Low dose of HQT medicated serum group 2.7 g/kg/day
Moderate dose of HQT medicated serum group 5.4 g/kg/day
High dose of HQT medicated serum group 10.8 g/kg/day
Fenofibrate-medicated serum group 0.4 g/kg/day
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FFA groups. The final concentration of FFA in each group was
1 mM.
LDH Assay of Each Medicated Serum on
L02 Cells
According to a previously described method (Yin et al., 2014), the
cytotoxicity of each medicated serum on L02 cells was evaluated
by the lactate dehydrogenase (LDH) release assay. Briefly, cells
were cultured with 10% vehicle serum, 10% low, moderate,
or high dose HQT-medicated serum, or 10% fenofibrate-
medicated serum for 24 h. LDH release in the supernatant
was detected using a colorimetric assay kit according to the
manufacturer’s instructions (Nanjing Jiancheng Bioengineering
Institute, Nanjing, China).
Biochemical Assay
To estimate the protective effects of HQT in FFA-induced
L02 cell injury, several biochemical parameters, such as
triglycerides (TG), aspartate aminotransferase (AST), alanine
aminotransferase (ALT), malondialdehyde (MDA), super-
oxidase dismutase (SOD), and glutathione (GSH) were
measured using a colorimetric assay kit from Nanjing Jiancheng
Bioengineering Institute (Nanjing, China). L02 cells were
cultured in a 6-well plate at a density of 1 × 105 per well and
allowed to grow to the desired confluence. The cells were then
treated for 24 h with Gibco RPMI-1640 containing various
concentrations of HQT-medicated serum (HL, HM, and HH) or
fenofibrate-medicated serum (FF), before stimulation with 1 mM
FFA for 24 h.
Analysis of ROS Generation
Levels of intracellular reactive oxygen species (ROS) in L02
cells were measured quantitatively and qualitatively using 2′,7′-
dichlorodihydrofluorescein diacetate (DCF-DA), a non-polar
dye that can diffuse into cells and then hydrolyze to non-
fluorescent 2′,7′-dichlorofluorescein (DCFH). ROS can oxidize
cellular DCFH to highly fluorescent dichlorofluorescein (DCF),
thus levels of intracellular ROS can be measured by the intensity
of fluorescence of DCF. In the present study, cells were seeded in
6-well plates at a density of 1 × 105/well. The cells were treated
for 24 h with Gibco RPMI-1640 containing HQT-medicated
serum (HL, HM, and HH), or fenofibrate-medicated serum (FF),
before stimulation with 1 mM FFA for 2 h, and incubation for
30 min with DCFH-DA (10 µM) at 37◦C. Levels of intracellular
ROS were determined by measuring the fluorescence density of
DCF using a SpectraMax M5 multifunctional microplate reader
(Molecular Devices, Shanghai, China).
Oil Red O Staining
Oil Red O staining was performed to facilitate lipid
visualization and quantification. L02 cells were fixed with
4% paraformaldehyde and stained with 0.7% Oil Red O solution
for 30 min at 25◦C. Cells were then washed and counterstained
with hematoxylin for 5 min. Images were acquired using the
Olympus BX51 image system (Olympus, Tokyo, Japan).
Inflammatory Cytokine Measurements
Expression of IL-6 and TNF-α were analyzed using ELISA
kits (MultiSciences, Hangzhou, China) according to the
manufacturer’s instructions. Absorbance was read at 450 nm
using a SpectraMax M5 multifunctional microplate reader
(Molecular Devices, Shanghai, China).
Transfection of Small Interference RNA
Human HSP27-specific siRNA and siRNA-control were designed
and synthesized by RiboBio Inc. (Guangzhou, China) for
transfection. The sense and antisense strands of HSP27-
specific siRNA were 5′-AUGAGACUGCCGCCAAGUAdTdT-
3′ and 5′-UACUUGGCGGCAGUCUCAUdTdT-3′, respectively.
Cells were plated in 6-well plates at 30–50% confluence, then
transfected with 50 nM siRNA-targeting HSP27 or 50 nM siRNA-
control using Lipofectamine 2000 (Life Science, CA, USA). After
6 h, 1 mL of Gibco RPMI-1640 containing 10% fetal bovine serum
was added to each well. Cells were transfected with siRNA for
24 h and then treated with, or without FFA and HQT-medicated
serum.
Cell Harvest and Protein Sample
Preparation
L02 cells were washed twice with ice-cold PBS and harvested
by scraping in cold PBS after the various treatments for each
group (control, FFA, and HH). After centrifugation at 1000 × g
for 10 min at 4◦C, cell pellets were collected and lysed in buffer
containing 8 M urea, 2 M thiourea, 4% CHAPS, 5% DNA enzyme,
and 5% RNA enzyme. The lysates were then intermittently
sonicated for 30 s. The resulting lysate was centrifuged at
12,000× g for 1 h at 4◦C, and the supernatant was collected. Total
protein concentration was measured using the Bradford method.
All samples were stored at−80◦C until further analysis.
iTRAQ Labeling
Proteins were precipitated following the addition of a fourfold
volume of cold acetone containing 10 mM DTT for about
2 h at −20◦C, and centrifugation at 12,000 × g for 20 min
at 4◦C, followed by air-drying and dissolution with 100 µL
TEAB dissolution buffer. The Bradford method was used to
quantify each protein sample. From each sample, 100 µg of
protein was reduced, alkylated, and then digested by Trypsin
(Promega, Madison, WI, USA) at 37◦C for 16 h, with the ratio of
protein : trypsin = 20:1, and labeled using the iTRAQ Reagent-8
plex Multiplex Kit (SCIEX, Framingham, MA, USA) according
to the manufacturer’s protocol. Two biological replicates were
carried out for the control group, and three biological replicates
for the FFA and HH groups. The control group samples were
labeled with 113 and 114; FFA group samples were labeled with
115, 116, and 117; HH group samples were labeled with 118,
119, and 121.
Strong Cation Exchange (SCX)
Chromatography
The iTRAQ labeled peptides were mixed in equal amounts
and fractioned by an HPLC system (Thermo Scientific Dionex
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UltiMate 3000 BioRS, Thermo Scientific, Shanghai, China) using
the Durashell C18 column (5 µm, 100 Å, 4.6 mm × 250 mm).
The dried peptides were dissolved in 100 µL buffer A (20 mM
NH4HCO3 in 3% acetonitrile, pH 10), and were then loaded
onto the HPLC device at a flow rate of 1 mL/min with buffer B
(20 mM NH4HCO3, pH 10) at gradients of 0–8% for 5 min; 8–
45% for 25 min; 45–80% for 15 min; and 80–100% for 5 min.
The eluted fractions were collected at 1-min intervals and pooled
into 12 fractions, then desalted with a Strata X C18 column
(Phenomenex, Guangzhou, China) and vacuum-dried.
LC-MS/MS Analysis
Liquid chromatography-electrospray ionization-tandem mass
spectrometry (LC-ESI-MS/MS) analysis was performed on the
AB Sciex non-LC-MS/MS (Triple TOF 5600 plus) system.
Peptides were loaded onto a 20 µm PicoFrit emitter (New
Objective) packed to 12 cm with Magic C18 AQ beads (3 µm, 120
Å) for the stationary phase. Chromatography was performed with
a 90-min gradient from 2 to 30% [buffer A: 0.1% (v/v) formic acid
and 5% (v/v) acetonitrile; buffer B: 0.1% (v/v) formic acid and
95% (v/v) acetonitrile]. MS1 spectra were collected in the range
350–1500 m/z for 250 ms. The 20 most intense precursors with
charge states 2–5 were selected for fragmentation. MS2 spectra
were collected in the range 50–2000 m/z for 100 ms. Precursor
ions were excluded from reselection for 15 s.
Data Processing and Analysis
The original MS/MS file data were submitted to the ProteinPilot
Software v 4.5 for analysis. The Paragon algorithm (Shilov
et al., 2007) was integrated into ProteinPilot against UniProt
human database (142483 items, updated April, 2015) for
database searching and protein identification. The parameters
were set as follows: the instrument was TripleTOF 5600,
for iTRAQ quantification, and cysteine was modified with
iodoacetamide; biological modifications included ID focus
and trypsin digestion. The Quantitate, Bias Correction, and
Background Correction were checked for protein quantification
and normalization. The resulting 1% global fits from FDR
corresponding to 99% correct protein identification was used
as an initial qualification criterion. In addition, only proteins
with at least one unique peptide and unused protein score
of >1.3 were considered for further analysis. Some of the
peptides identified were excluded from the quantitative analysis
for one of the following reasons: (i) peaks corresponding
to the iTRAQ labels were not detected; (ii) peptides were
identified with low identification confidence; (iii) peptides
were claimed by more than one protein; (iv) S/N (signal-to-
noise ratio) for any peptide ratio was too low; (v) combined
feature probability<30%, such as semi-tryptic peptides, peptides
missing an iTRAQ reagent label, and those with low probability
modifications, or large delta masses. For biological replicates
or technological replicates, the average fold change induced by
treatment relative to the control or FFA group was defined.
Statistically significant differences between expression levels
of the proteins in various samples were determined by the
Student’s t-test (two-tailed or unpaired), and the minimum
values among replicates were treated as the final P-values. Data
were expressed as mean ± SD. For protein abundance ratios
measured with iTRAQ, we took fold changes ≥1.2 (or ≤0.83)
and P-values < 0.05 were taken as the thresholds to identify
significant changes.
Bioinformatic Analysis of Proteins
For bioinformatic analyses, differentially expressed proteins
were classified based on annotations from the UniProt
Knowledgebase1. GO functional classification was performed
with the Blast2GO software (v4.5 pipeline5). The KEGG
databases2 were used to access current knowledge on biochemical
pathways and other types of molecular interactions. Both GO
and KEGG pathway enrichment analyses were used to uncover
the enriched pathways of significantly altered proteins and to
identify their functions.
Immunoblotting Analysis
Cell culture medium was removed from each well, rinsed twice
with PBS, and lysed with EnoGeneTM Total Protein Extraction
Kit (KeyGEN Biotechnology, Nanjing, China), according to
the manufacturer’s instructions. Total protein concentrations
were determined by the Bradford method, and equal amounts
of proteins from different groups were separated via 12 or
15% sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) following standard protocols. Primary antibodies
including anti-human polyclonal antibodies that recognize
ACAT1, CANX, ILK, and GAPDH purchased from Proteinteach
Group (Wuhan, China); rabbit anti-human phospho-HSP27
(Ser15) antibody and HSP27 antibody purchased from Affinity
Bioscience (USA); and secondary antibodies, goat anti-rabbit
horseradish peroxidase (HRP)-IgG purchased from Zhongshan
Golden Bridge Biotechnology Co, Ltd. (Beijing, China) were used
in the present study.
Statistical Analysis
Statistical significance was analyzed using the Student’s t-test
(paired or unpaired) or one-way analysis of variance (ANOVA)
with the GraphPad Prism software (version, 5.0). Data are
presented as mean ± standard deviation (SD). Differences were
considered to be statistically significant at p< 0.05.
1http://www.uniprot.org/
2http://www.genome.ad.jp/kegg/pathway.html
TABLE 2 | Lactate dehydrogenase (LDH) release assay for each medicated
serum treatment.
Group information of medicated serum treatment LDH release (U/L)
Vehicle control group 102.45 ± 14.02
10% vehicle serum group 108.01 ± 10.211
10% Low dose of HQT medicated serum group 109.86 ± 14.431
10% Moderate dose of HQT medicated serum group 111.70 ± 10.981
10% High dose of HQT medicated serum group 112.74 ± 11.861
10% Fenofibrate-medicated serum group 108.97 ± 15.361
1p > 0.05.
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RESULTS
Cytotoxic Effects of Each Medicated
Serum on L02 Cells
First, LDH release in supernatant was measured to evaluate the
cytotoxic effects of each medicated serum on L02 cells. The
results showed that 10% vehicle serum, 10% HQT-medicated
serum (low, moderate, high), and 10% fenofibrate-medicated
serum treatments have no significant difference on LDH release
(p > 0.05), compared with the vehicle control group (Table 2),
indicating that each medicated serum treatment has no cytotoxic
effects on L02 cells.
Effects of HQT-Medicated Serum in
FFA-Induced LO2 Cells
Production of MDA in the culture supernatant, activity of SOD,
and intracellular levels of GSH and ROS were all measured in
the present study to evaluate whether HQT-medicated serum
protects L02 cells injured by FFA. The results showed that
production of MDA in the culture supernatant and intracellular
FIGURE 1 | Effects of Hugan Qingzhi (HQT)-medicated serum on levels of MDA (A), ROS (B), SOD (C), GSH (D), TG (E), and AST, ALT (F) in free fatty acid
(FFA)-stimulated L02 hepatocytes over 24 h. Values are expressed as mean ± SD in each group. ∗∗p < 0.01 vs. control group; #p < 0.05 vs. FFA group; ##p < 0.01
vs. FFA group.
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ROS stimulated by FFA for 24 h were significantly increased
compared with the control group (Figures 1A,B). In contrast,
SOD activity and GSH levels were reduced (Figures 1C,D). In
comparison with the FFA group, the HQT-medicated serum
group exhibited not only a down-regulation of MDA production
and intracellular ROS, but also an up-regulation of SOD activity
and GSH levels in a dose-dependent manner. HQT-medicated
serum also showed an ability to inhibit FFA-induced intracellular
triglyceride (TG) accumulation (Figure 1E) in L02 hepatocytes.
In the Oil Red O staining assay, treatment of L02 cells with FFA
resulted in a considerable increase in TG accumulation, whereas
treatment with HQT-medicated serum significantly attenuated
TG accumulation (Figure 2), a finding that is consistent with
those presented in Figure 1E. In comparison with the FFA group,
AST and ALT levels in the culture supernatant of the HQT-
medicated serum treatment group were significantly reduced
(Figure 1F). In the assay to detect TNF-α and IL-6, both
showed a significant increase in FFA-treated cells, compared with
the control group, whereas cells treated with HQT-medicated
serum showed a marked inhibitory effect (Figures 3A,B). These
results all suggest that HQT-medicated serum can regulate
oxidative stress and inflammatory cytokine production, as well
as ameliorate intracellular TG accumulation to achieve an anti-
NAFLD effect.
Quantitative Identification of
Differentially Expressed Proteins Using
iTRAQ in L02 Cells
The protective effects of HQT-medicated serum have been
proven on FFA-stimulated L02 cells. However, the molecular
mechanisms of HQT-medicated serum on FFA-induced L02
cell damage are still not fully understood. Thus, an iTRAQ-
based proteomic method was used to analyze the molecular
mechanisms of this process. After merging data from the
respective replicates, 4307 proteins were identified, of which,
3586 (83.26%) contained at least two unique peptides. Moreover,
4268, 4269, and 4269 proteins were quantified in FFA:C,
HH:C, and HH:FFA, respectively. Further analysis identified
that there were 355 (169 up-regulated, 186 down-regulated),
365 (203 up-regulated, 162 down-regulated), and 359 (232 up-
regulated, 127 down-regulated) differentially expressed proteins
in FFA:C, HH:C, and HH:FFA, respectively (Table 3 and
Supplementary Table S1). The Venn-diagram in Figure 4 shows
the overlap of all differentially expressed proteins among the
three groups.
Bioinformatics Analysis of Differentially
Expressed Proteins (DEPs)
GO analysis was performed to functionally classify the
differentially expressed proteins (DEPs), with the proteins
categorized according to biological process (BP), cellular
components (CC), and molecular functions (MF) using the
Blast2GO software (v4.5 pipeline5). As shown in Figure 5,
proteins were separated according to their BP into 26
subcategories that included the following: cellular process
(11.13%), metabolic process (9.91%), biological regulation
FIGURE 2 | Effects of HQT-medicated serum on TG examination in
FFA-stimulated L02 hepatocytes over 24 h following Oil Red O staining
(40 × 10 magnification). Control, control group; FFA, free fatty acid group;
HL, FFA + 10% low dose HQT-medicated serum group; HM, FFA + 10%
moderate dose HQT-medicated serum group; HH, FFA + 10% high dose
HQT-medicated serum group; FF, FFA + 10% fenofibrate-medicated serum
group.
(7.89%), regulation of BP (7.41%), CC organization or biogenesis
(6.73%), localization (4.97%), and developmental process
(5.52%), among others. The eight main CC subcategories
were: cell (16.69%), cell part (16.69%), organelle (16.13%),
organelle part (13.27%), membrane-enclosed lumen (8.82%),
macromolecular complex (9.03%), extracellular region part
(8.77%), and extracellular region (8.85%). The four major MF
subcategories were: binding (50.64%), catalytic activity (25.11%),
enzyme regulator activity (4.61%), and structural molecular
activity (7.00%).
The DEPs were further characterized in FFA:C, HH:C,
and HH:FFA, respectively, using GO enrichment analysis
(Supplementary Figures S1–S3). Several differences were noted
in the percentages of some GO terms. For example, only down-
regulated proteins showed antioxidant activity in FFA:C. In
HH:C, however, both down-regulated and up-regulated proteins
showed antioxidant activity. For electron carrier activity, the
percentage of up-regulated proteins was higher than that of
down-regulated proteins in FFA:C, whereas this phenomenon
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FIGURE 3 | Effects of HQT-medicated serum on the levels of TNF-α and IL-6 (A,B) in free fatty acid (FFA)-stimulated L02 hepatocytes over 24 h. Values are
expressed as mean ± SD in each group. ∗∗p < 0.01 vs. control group; #p < 0.05 vs. FFA group; ##p < 0.01 vs. FFA group.
TABLE 3 | Number of differentially expressed proteins identified in
experiments.
Sample pairs FFA: C HH: C HH: FFA
Quantified 4268 4269 4269
Up-regulated 169 203 232
Down-regulated 186 162 127
Total difference 355 365 359
C, the control group; FFA, free fatty acid group (1 mM); HH, FFA + 10% high dose
HQT-medicated serum group.
was reversed in HH:C. These results suggest that HQT-medicated
serum protects FFA-induced L02 cell damage by improving
antioxidant activity, an action that might be directly or indirectly
associated with its actions in the mitochondrial electron transport
chain.
To analyze the biological pathways that responded to FFA-
induced damage and the effects of HQT-medicated serum
in FFA:C, HH:C, and HH:FFA, respectively, all DEPs were
further analyzed using the KEGG database. A total of
315, 322, and 313 proteins were categorized in FFA:C
(151 up-regulated, 164 down-regulated), HH:C (174 up-
regulated, 148 down-regulated), and HH:FFA (197 up-regulated,
116 down-regulated), respectively (Supplementary Table S2).
Among the DEPs in FFA:C, HH:C, and HH:FFA, a total
of 185, 179, and 187 biological pathways were annotated,
respectively (Supplementary Table S3). It was also found
that many pathways among the three groups were enriched,
including microbial metabolism in diverse environments, fatty
acid metabolism, PPAR signaling pathway, and mitogen-
activated protein kinase (MAPK) signaling pathways, among
others.
Verification of Differentially Expressed
Proteins by Western Blotting
Several iTRAQ-identified proteins were selected for validation
by western blotting, including acetyl-CoA acetyltransferase 1
FIGURE 4 | Venn-diagram showing overlap of all differentially
expressed proteins among FFA: C, HH: FFA, and HH: C.
(ACAT1), integrin linked kinase (ILK), heat shock protein 27
(HSP27, also referred to as HSPB1), and calnexin (CANX).
These proteins were annotated into four signaling pathways:
fatty acid metabolism (ACAT1), PPAR signaling pathway (ILK),
MAPK signaling pathway (HSP27), and protein processing in
the endoplasmic reticulum (ER; CANX). Results showed that
in comparison with the control group, ACAT1 and CANX
were up-regulated by FFA treatment alone, whereas ILK and
phosphorylated HSP27 were down-regulated. In comparison
with the FFA group, expression of these proteins was reversed
in the HQT-medicated serum group (Figures 6, 7). The results
detected by immunoblotting analysis were consistent with those
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FIGURE 5 | Gene Ontology (GO) analysis of all differentially expressed proteins. Proteins were classified according to biological process (BP), cellular
component (CC), and molecular function (MF) by Blast2GO software (v4.5 pipeline5).
of iTRAQ-identification, indicating that the protective effects of
HQT-medicated serum in L02 hepatocyte damage induced by
FFA are associated with expression and function of the respective
proteins.
Role of HSP27 in FFA-Induced L02 Cell
Damage and Effects of HQT-Medicated
Serum
Among the four validation proteins, the expression level of
HSP27 in the present study was remarkable. HSP27 is a
multidimensional protein with several functions, which is usually
activated in response to cellular stress, including oxidative stress
and chemical stress. In the present study, FFA treatment over
24 h resulted in a decline in HSP27 activity, as determined
by immunoblotting analysis with an antibody against the
phosphorylated form of HSP27. These findings are consistent
with those of iTRAQ-identification. In contrast, HQT-medicated
serum caused an increase in HSP27 activity in LO2 cells. Thus, to
investigate further the activity of HSP27 during FFA treatment,
the expression levels of phospho-HSP27 and total HSP27 were
detected following FFA treatment at different intervals.
As shown in Figure 8, expression of phosphorylated HSP27
was increased following FFA treatment in a time-dependent
manner for 4 h, and later declined as treatment time increased.
Moreover, total HSP27 expression showed a consistent decline
with time, as FFA treatment progressed.
To determine the involvement of HSP27 in FFA-stimulated
L02 cells and the effects of HQT-medicated serum, specific
siRNA against HSP27 was applied to L02 cells. As shown in
Figures 9A,B, HSP27 siRNA significantly knocked down total
and phosphorylated HSP27 expression. Levels of ROS, IL-6, and
TNF-α were again evaluated after HSP27 was knocked down,
as shown in Figures 9C–E. In normal cells, HQT-medicated
serum significantly attenuated FFA-induced ROS, IL-6, and TNF-
α production compared with FFA treatment alone. Nevertheless,
in HSP27 knocked down cells, the attenuated effects of HQT-
medicated serum on ROS (p = 0.1945), IL-6 (p = 0.03), and
TNF-α (p = 0.28) production induced by FFA were weakened,
compared with the FFA group. When combined, these data
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FIGURE 6 | Effects of HQT-medicated serum on amount of phosphorylated HSP27 and total HSP27 (A,B) and phosphorylation level of HSP27 (A,C) in
FFA-stimulated L02 hepatocytes over 24 h. GAPDH was used as a loading control. Values are expressed as mean ± SD in each group. ∗∗p < 0.01 vs. control
group; ##p < 0.01 vs. FFA group.
suggest that activation of HSP27 inhibits FFA-induced ROS, IL-6,
and TNF-α production, and that the protective effects of HQT-
medicated serum in FFA-induced L02 cell damage are associated
with its regulation of HSP27.
DISCUSSION
A previous study demonstrated that the anti-hepatic steatosis
effect of HQT in L02 hepatocytes inhibits SREBP-1 expression
and increases CPT-1 and ACOX-1 expression via activation
of the AMPK and PPAR-α pathways (Yin et al., 2014).
Although that study provided evidence of the anti-hepatic
steatosis and antioxidant effects in FFA-induced L02 hepatocyte
damage, the molecular mechanism underlying the protective
effects of HQT remained largely unknown. As a follow-
up, the present study employed quantitative proteomics to
elucidate the underlying mechanisms of HQT in FFA-induced
L02 hepatocyte damage. The results of biochemical assays
(including AST, ALT, and MDA, etc.) further confirmed the
protective effect of HQT in FFA-induced L02 hepatocyte
damage, consistent with the results of the previous study
(Yin et al., 2014). Furthermore, proteomic analysis revealed
that HQT protects against L02 hepatocyte injury induced by
FFA, and is associated with protein processing in the ER,
fatty acid metabolism, and the PPAR and MAPK signaling
pathways.
Accumulation of intrahepatic TG (hepatic steatosis) is one of
the most remarkable and characteristic changes associated with
NAFLD, and usually occurs when the rate of fatty acid input is
greater than that of the output. There are two aspects to fatty
acid input: de novo synthesis and uptake from food. Output
entails fatty acid oxidation and esterification to produce TG.
TG are either incorporated into lipoproteins or stored as lipid
droplets (Kohjima et al., 2007). Therefore, proteins involved in
fatty acid metabolism are likely to play an important role in
processes associated with NAFLD. In the present study, ACAT1
was up-regulated in the FFA group compared with the control
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FIGURE 7 | Effects of HQT-medicated serum on expression of ACAT1 (A,B), ILK (A,C), and CANX (A,D) expression in FFA-stimulated L02 hepatocytes over
24 h. GAPDH was used as a loading control. Values are expressed as mean ± SD in each group. ∗∗p < 0.01 vs. control group; ##p < 0.01 vs. FFA group.
group, and was inhibited by HQT-medicated serum. ACAT1
is responsible for cholesteryl ester (CE) synthesis. In most cell
types, CE mainly stored as cytoplasmic lipid droplets (Chang
et al., 1997). On the other hand, the up-regulation of ACAT1 is
noticeable in NAFLD, which is accompanied by over-production
of cholesterol (Nakamuta et al., 2009). Over production of
cholesterol can lead to increased levels of oxysterols, activation of
LXR-α and SREBP-1, and enhance fatty acid synthesis (Nakamuta
et al., 2009). Therefore, ACAT1 may be a potential marker of
NAFLD, suggesting that the anti-hepatic steatosis effect of HQT
is associated with regulation of ACAT1.
Accumulation of TG within hepatocytes caused by
abnormalities in lipid metabolism and disposition is the
“first hit” in development of NAFLD (Basaranoglu et al., 2013).
An additional stressor in the incidence and development
of NAFLD is sometimes referred to as a “second hit,” and
can include oxidative stress and the inflammatory response
(Basaranoglu et al., 2013). Several pathways, including the
MAPK pathway, participate in the progression of oxidative
stress and the inflammatory response. The present showed that
in comparison with the control, HSP27 is inactivated by FFA
treatment over 24 h, and activated by HQT, when compared
with the FFA group. Moreover, the expression of phosphorylated
HSP27 was increased by FFA treatment in a time-dependent
manner for 4 h and declined thereafter as FFA treatment
progressed, indicating that levels of phosphorylated HSP27
changed dynamically during FFA treatment. It is speculated
that FFA induces a transient increase in phosphorylated
HSP27 in L02 hepatocytes. Furthermore, sustained exposure
to metabolic stress might reduce levels of phosphorylated
HSP27, suggesting that L02 hepatocytes failed to exhibit a
robust physiological defense to prolonged cellular stress. Other
studies have reported that HSP27 is a reversibly phosphorylated
protein which is controlled by protein kinases and phosphatases.
Protein kinases can phosphorylate HSP27 in response to
cellular stress, including oxidative stress and chemical stress,
and thereby demonstrate protective effects under stressful
conditions (Ferns et al., 2006; Thomas et al., 2008). On the
other hand, phosphorylation of HSP27 is also controlled by
phosphatases that effect dephosphorylation of HSP27 (Berrou
and Bryckaert, 2009; Kostenko and Moens, 2009). Moreover,
one clinical study reported that HSP27 is down-regulated
in ballooned hepatocytes of patients with NASH, indicating
that the in vitro model of NAFLD established in the present
study is very similar to that of clinical NASH with ballooning
degeneration (Sookoian et al., 2016). Furthermore, using
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FIGURE 8 | Dynamic changes in the amounts of phosphorylated HSP27 and total HSP27 (A,B), and phosphorylation level of HSP27 (A,C) during the
process of FFA treatment. GAPDH was used as a loading control. Values are expressed as mean ± SD in each group. ∗∗p < 0.01 vs. 0 h group.
HSP27-specific siRNA, it was discovered that the inhibition
effects of HQT on ROS generation and production of IL-
6 and TNF-α in FFA-treated L02 hepatocytes are involved
in recovery, following activation of HSP27. These findings
indicate that HSP27 plays an important role in progression of
NAFLD, and HQT attenuates FFA-induced oxidative stress and
the inflammatory response by promoting recovery, after the
activation of HSP27.
A growing body of evidence has shown that hepatocyte
death plays a pivotal role in transition of NAFLD to NASH.
Abnormal accumulation of fatty acids in the liver stimulates ROS
generation, which can directly induce DNA/protein damage and
promote hepatic failure via activation of stress-related signaling
pathways, including the MAPK and PPAR pathways (Hardwick
et al., 2009). In the present study, ILK was involved in the
PPAR pathway. Moreover, HQT can reverse ILK expression
induced by FFA to normal levels, because ILK activation in
mammalian cells results in suppression of apoptosis and anoikis
(Wu and Dedhar, 2001; Li et al., 2016). Thus, HQT might
inhibit FFA-induced L02 hepatocyte damage by recovering ILK
expression.
The ER is the cellular site of Ca2+ storage for synthesis,
folding, and maturation of most secreted and trans-membrane
proteins. Disturbed hepatic cholesterol homeostasis and free
cholesterol accumulation in the liver results in increased
oxidative stress, leading to ER stress that is closely associated with
the development of NAFLD and entails fat accumulation, insulin
resistance, inflammation, and apoptosis among other conditions
(Samali et al., 2010; Bozaykut et al., 2016). Moreover, CANX, an
ER-induced protein, is reportedly up-regulated during ER stress,
indicating its importance as a marker of ER stress (He et al.,
2016; Ryan et al., 2016). In the present study, HQT inhibited FFA-
induced CANX over-expression that was annotated in protein
processing in the ER. This finding suggests that the protective
effect of HQT is associated with regulation of ER stress.
In the proteomics data, KEGG enrichment analysis revealed
that among all DEPs, a total of 31, 21, and 35 proteins from
FFA:C, HH:FFA, and HH:C, respectively, were enriched in
microbial metabolism in diverse environments. This indicates
that development of NAFLD is closely related to microbial
metabolism in the host. However, no follow-up evaluations,
such as determination of the diversity of gut microbiota,
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FIGURE 9 | Expression of total and phosphorylated HSP27 after treatment with HSP27 siRNA (A,B). Effects of HQT-medicated serum on levels of ROS,
TNF-α, and IL-6 induced by free fatty acids (FFA) in normal L02 cells and HSP27 knockdown L02 cells (C–E). GAPDH was used as a loading control. Values are
expressed as mean ± SD in each group. ∗∗p < 0.01 vs. control group; ##p < 0.01 vs. FFA group; &&p < 0.01 vs. si-HSP27 group; ∗&p < 0.05 vs. FFA + si-HSP27
group.
were performed in the present study to confirm these results.
A growing body of evidence suggests that gut microbiota
act as regulators of energy homeostasis and fat deposition,
thereby implicating them in the development of obesity and
metabolic disease (Cope et al., 2000; Nair et al., 2001; Rao, 2008).
Moreover, changes in secondary metabolites, such as ethanol,
ammonia, phenols, and lipopolysaccharide (LPS), induced by
alterations in gut microbiota communities can exert the effects
of endotoxins which can stimulate the incidence of oxidative
stress and inflammation (Aqel and DiBaise, 2015). Therefore,
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gut microbiota communities could have a crucial role in
the progression of NAFLD and could be associated with the
protective effect of HQT.
CONCLUSION
Using the combined strategy of iTRAQ with LC-MS/MS and
subsequent investigation, this study confirmed that HQT has
excellent protective effects in FFA-induced L02 hepatocyte
injury. These effects were associated with the reduction of
lipid accumulation, oxidative stress, and inflammation, and
inhibition of ER stress and hepatocyte death. Subsequent
validation experiments proved that ACAT1, HSP27, ILK,
and CANX might be associated with the protective effect
of HQT in the FFA-induced L02 hepatocyte injury model.
Moreover, bioinformatic analysis of the DEPs results showed
that microbial metabolism in diverse environments was strongly
associated with the protective effect of HQT in FFA-induced
L02 hepatocytes, suggesting a key role for the gut microbiota
in progression of NAFLD. Consequently, the present study
not only expands our understanding of the pathogenesis of
NAFLD, and provides new insights for its treatment, but
further elucidates the underlying mechanism of the effects of
HQT in NAFLD treatment. Further studies are needed to
clarify the role of DEPs in the effects of HQT in NAFLD
treatment, in particular in primary cells or even in vivo
study.
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